Gilead Sciences (GILD) Liabilities and Shareholders Equity (2016 - 2025)
Gilead Sciences' Liabilities and Shareholders Equity history spans 17 years, with the latest figure at $59.0 billion for Q4 2025.
- For Q4 2025, Liabilities and Shareholders Equity changed 0.05% year-over-year to $59.0 billion; the TTM value through Dec 2025 reached $229.7 billion, up 2.83%, while the annual FY2025 figure was $59.0 billion, 0.05% changed from the prior year.
- Liabilities and Shareholders Equity reached $59.0 billion in Q4 2025 per GILD's latest filing, up from $58.5 billion in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $68.0 billion in Q2 2021 to a low of $53.6 billion in Q2 2024.
- Average Liabilities and Shareholders Equity over 5 years is $61.2 billion, with a median of $62.2 billion recorded in 2023.
- Peak YoY movement for Liabilities and Shareholders Equity: increased 21.54% in 2021, then fell 14.05% in 2024.
- A 5-year view of Liabilities and Shareholders Equity shows it stood at $68.0 billion in 2021, then dropped by 7.04% to $63.2 billion in 2022, then decreased by 1.66% to $62.1 billion in 2023, then fell by 5.04% to $59.0 billion in 2024, then increased by 0.05% to $59.0 billion in 2025.
- Per Business Quant, the three most recent readings for GILD's Liabilities and Shareholders Equity are $59.0 billion (Q4 2025), $58.5 billion (Q3 2025), and $55.7 billion (Q2 2025).